

Supplementary Table 3. Risk of CAC progression according to sex (817 male and 198 female)

Variable	Unadjusted HR (95% CI)	P value	Variable	Unadjusted HR (95% CI)	P value
Male			Female		
Clinical and laboratory parameters			Clinical and laboratory parameters		
Age (per 10 years increment)	1.22 (1.07–1.42)	0.004	Age (per 10 years increment)	1.99 (1.31–3.04)	0.001
Current smoking	1.57 (1.47–1.73)	<0.001	Current smoking	2.14 (0.29–15.72)	0.454
Hypertension	1.56 (1.08–2.77)	0.004	Hypertension	1.17 (0.62–1.63)	0.591
Diabetes mellitus	2.50 (2.18–2.91)	0.001	Diabetes mellitus	2.17 (1.14–4.11)	0.018
Dyslipidemia	1.38 (1.10–1.73)	0.005	Dyslipidemia	1.65 (0.84–3.22)	0.143
Chronic kidney disease	1.10 (0.85–1.61)	0.622	Chronic kidney disease	1.48 (0.70–3.63)	0.392
High FRS	1.75 (1.40–2.23)	0.007	High FRS	1.05 (0.95–1.16)	0.376
Prior use of antiplatelet agent	0.92 (0.68–1.05)	0.073	Prior use of antiplatelet agent	0.95 (0.91–1.37)	0.091
Prior use of statin	0.87 (0.56–1.35)	0.537	Prior use of statin	2.10 (1.15–3.83)	0.016
SBP \geq 140 mm Hg	1.71 (1.04–2.27)	0.016	SBP \geq 140 mm Hg	1.42 (0.97–1.78)	0.237
Triglyceride \geq 200 mg/dL	1.35 (0.83–2.33)	0.683	Triglyceride \geq 200 mg/dL	0.68 (0.18–1.22)	0.119
HDL-C < 40 mg/dL	0.87 (0.65–1.17)	0.350	HDL-C < 40 mg/dL	0.98 (0.50–1.92)	0.941
LDL-C \geq 160 mg/dL	0.85 (0.40–2.45)	0.859	LDL-C \geq 160 mg/dL	1.56 (1.05–8.16)	0.003
Fasting glucose \geq 100 mg/dL	1.23 (1.04–1.50)	0.006	Fasting glucose \geq 100 mg/dL	1.59 (0.87–2.91)	0.133
hs-CRP \geq 2.0 mg/L	1.18 (1.01–1.63)	0.039	hs-CRP \geq 2.0 mg/L	0.73 (0.28–1.90)	0.524
HOMA-IR \geq 3.0	0.92 (0.67–1.25)	0.584	HOMA-IR \geq 3.0	0.76 (0.14–1.62)	0.234
Obesity-related parameters			Obesity-related parameters		
BMI \geq 25 kg/m ²	1.41 (1.14–1.75)	0.002	BMI \geq 25 kg/m ²	1.13 (0.61–1.82)	0.708
WC \geq 90 cm (male) or 85 cm (female)	1.17 (1.05–1.54)	0.008	WC \geq 90 cm (male) or 85 cm (female)	0.86 (0.53–1.70)	0.658
TAT ^a	1.00 (1.00–1.01)	0.309	TAT ^a	1.00 (0.99–1.00)	0.997
VAT ^a	1.02 (1.01–1.05)	0.028	VAT ^a	1.01 (0.94–1.08)	0.789
Highest quartile of VAT (Q4)	1.80 (1.33–2.04)	<0.001	Highest quartile of VAT (Q4)	1.44 (1.13–2.32)	0.022
Height-indexed VAT ^b	1.02 (1.00–1.09)	0.064	Height-indexed VAT ^b	1.00 (0.99–1.01)	0.715
SAT ^a	0.99 (0.99–1.00)	0.202	SAT ^a	0.99 (0.99–1.00)	0.022
VAT/SAT ratio	2.63 (2.24–3.28)	<0.001	VAT/SAT ratio	3.22 (2.48–6.42)	<0.001
VAT/SAT ratio \geq 1.30	2.81 (2.38–3.39)	<0.001	VAT/SAT ratio \geq 1.30	3.52 (1.86–6.67)	<0.001

CAC, coronary artery calcification; HR, hazard ratio; CI, confidence interval; FRS, Framingham risk score; SBP, systolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; HOMA-IR, homeostatic model assessment for insulin resistance; BMI, body mass index; WC, waist circumference; TAT, total adipose tissue; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.

^aTotal, visceral, and subcutaneous fat area were assessed per 1 cm² increment, ^bHeight-indexed visceral fat area was assessed per 1 cm²/m increment.